Drug Profile
VIR 002
Alternative Names: VIR-002Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer ViRAZE
- Class Antivirals; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Smallpox
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for preclinical development in Smallpox in USA